Skip to main content

Advertisement

Table 3 Two-way sensitivity analysis: impact of simultaneously varying the QALY adjustment and proportion of BSI represented by Candida on the estimate of cost per QALY of MIC vs. FLU

From: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

QALY conversion factor Candidemia as percentage of all BSI
  0.048 0.100 0.140 0.200 0.250 0.283
0.44 $50,722 $50,609 $50,522 $50,391 $50,282 $50,210
0.50 $44,636 $44,536 $44,459 $44,344 $44,248 $44,185
0.55 $40,578 $40,487 $40,417 $40,313 $40,226 $40,168
0.60 $37,196 $37,113 $37,049 $36,953 $36,874 $36,821
0.64 $34,872 $34,794 $34,734 $34,644 $34,569 $34,520
0.70 $31,883 $31,811 $31,757 $31,674 $31,606 $31,561
0.75 $29,757 $29,691 $26,639 $29,563 $29,499 $29,457
0.80 $21,897 $27,835 $27,787 $27,715 $27,655 $27,616
  1. BSI = blood stream infection; FLU = fluconazole; MIC = micafungin; QALY = quality-adjusted life year.